Boston Scientific has completed a multi-year share repurchase program, buying back 39,922,436 shares for about US$2.0 billion, representing 2.69% of the company's shares. The completed buyback provides an additional data point on how Boston Scientific is allocating capital and managing its share count. At the latest share price of US$51.83, the stock has seen a 20.42% one-month return, although the year-to-date return is down 45.28% and the one-year total shareholder return has fallen 49.76%. On the most followed valuation view, Boston Scientific's fair value of $72.25 sits well above the recent share price, suggesting the stock is 28.3% undervalued. Investors also need to watch for risks around tariff-related cost headwinds and ongoing competitive and regulatory pressure on products like WATCHMAN.
Boston Scientific CorpCompleted $2.0B buyback of 39.9M shares, signaling capital allocation and reducing share count.
